Harrow (HROW) EBIT Growth (1y) (2011 - 2026)
Harrow (HROW) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Harrow | 1.55 Bn | 1.47 Bn | 50.36 Mn | -196.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -196.48% |
| Mar 31, 2026 | -96.58% |
| Dec 31, 2025 | 20.87% |
| Sep 30, 2025 | 1,016.35% |
| Jun 30, 2025 | 645.69% |
| Mar 31, 2025 | -62.12% |
| Dec 31, 2024 | 364.59% |
| Sep 30, 2024 | -24.25% |
| Jun 30, 2024 | -34.95% |
| Mar 31, 2024 | -672.56% |
| Dec 31, 2023 | -174.18% |
| Sep 30, 2023 | 1,955.32% |
| Jun 30, 2023 | 39.17% |
| Mar 31, 2023 | -42.41% |
| Dec 31, 2022 | -1.31% |
| Sep 30, 2022 | 97.47% |
| Jun 30, 2022 | -59.46% |
| Mar 31, 2022 | -27.97% |
| Dec 31, 2021 | -166.83% |
| Sep 30, 2021 | -332.75% |